Shigella’s Rising Threat: A Call for Vigilant Diagnostics and New Vaccines
A major prospective, facility-based surveillance study from the Enterics for Global Health (EFGH) network reveals the substantial burden and escalating antimicrobial resistance of Shigella bacteria in young children across low- and middle-income countries. The research, published in The Lancet Global Health, provides critical epidemiological data on the incidence of Shigella-attributable diarrhoea, a leading cause of childhood morbidity. The study’s findings highlight that current leading quadrivalent vaccine candidates cover the majority of circulating Shigella serotypes, offering a promising path forward. This work underscores the dual public health crisis of a common infection becoming increasingly difficult to treat with standard antibiotics, placing greater emphasis on the role of accurate microbiology testing and antimicrobial susceptibility testing in guiding patient care and tracking resistance patterns.
Study Significance: For professionals in laboratory medicine, these findings directly impact infectious disease panels and antimicrobial susceptibility testing protocols. The data affirm the readiness of global surveillance sites for rigorous vaccine trials, which will require high-fidelity serology and molecular diagnostics to monitor vaccine efficacy and shifting serotype prevalence. This study reinforces the need for clinical laboratories to prioritize accurate pathogen identification and resistance profiling to combat this growing public health threat.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
